Oct 4, 2007 (PrimeNewswire via COMTEX News Network) -- Results Presented Today At the Congress of the German Society for Stem Cell Research in Wurzburg, Germany Early Clinical Data Supporting Use of Aastrom Bone Repair Cells (Brcs) in Treatment of Osteonecrosis of the Femoral Head Also Presented

ANN ARBOR, Mich., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced today that the company will be restating its financial statements for all periods included in an amended annual report on Form 10-K/A for the fiscal period ended June 30, 2010, as well as amended

ANN ARBOR, Mich., July 30, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has completed the previously announced

Results Demonstrate Reparative Properties of Unique Macrophage Population Found in Ixmyelocel-T and Potential Role in Reverse Transport of Cholesterol

Ronnda L. Bartel, Ph.D., Named Chief Scientific Officer; Sharon Watling, Pharm.D., Appointed Vice President of Clinical and Regulatory Affairs

Manufacturing of MACI in Denmark to be discontinued Sales of MACI in Europe, representing 1% of revenues in 2014, temporarily ceased U.S. action plan implemented to optimize R&D, manufacturing and commercial operations Measures expected to enable company to generate positive cash flow from the U.S.

Industry Veteran and Aastrom Board Member, Tim Mayleben, to Become New CEO in December 2009; Expected That George Dunbar, Current CEO, Will Become Chairman of the Board; Transitions to Strengthen and Expand Senior Management Team to Become Effective Immediately After Company's Annual Meeting Currently Set for December 14, 2009

Six-Month Interim Results in Study of Patients With Severe Cardiovascular Disease to be Presented Later This Year

Company Plans to Initiate Phase 3 Planning Discussions With the FDA and Report Six-Month Interim Results for all Enrolled Patients Later This Year

ANN ARBOR, Mich., Nov. 20, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the first patient has been treated in its randomized, controlled, prospective, open-label IMPACT-DCM clinical trial.